Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan : A Belgian analysis

Annemans, L.;Van Cutsem, Eric;Humblet, Yves;Van Laethem, Jean-Luc;Bleiberg, H.
(2007) Acta Clinica Belgica (Multilingual Edition) — Vol. 62, n° 6, p. 419-425 (2007)

Files

36806.pdf
  • Restricted Access
  • Adobe PDF
  • 348.45 KB
Request a copy

Details

Authors
  • Annemans, L.
    Author
  • Van Cutsem, EricKUL
    Author
  • Humblet, YvesUCLouvain
    Author
  • Van Laethem, Jean-Luc
    Author
  • Bleiberg, H.
    Author
Abstract
This analysis compared the cost-effectiveness in Belgium of cetuximab plus irinotecan with current current care in the treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (CRC) that has failed irinotecan-containing therapy. Treatment outcomes and medical resource use data for patients receiving cetuximab plus irinotecan from the BOND study were compared with those from a matched group of patients (current care) (n = 66). Two scenarios were considered in which cetuximab was discontinued either at 6 weeks or at 12 weeks if there was no tumour response at those time points. Cost-effectiveness was expressed in Euros as the additional cost per additional life year gained (LYG) (referred to as the incremental cost-effectiveness ratio (ICER)). For the 6-week rule, the ICERs were is an element of 17000 compared with current care. For the 12-week rule, the ICER was:is an element of 40000 /LYG. Sensitivity analyses revealed that, in the worst case, considering all assumptions against the cetuximab combination, the maximum ICER is:is an element of 30000 or is an element of 59000. In conclusion, cetuximab plus irinotecan for patients with metastatic CRC, after failure on irinotecan-containing chemotherapy, is rather cost-effective compared with current care in both scenarios tested.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Annemans, L., Van Cutsem, E., Humblet, Y., Van Laethem, J.-L., & Bleiberg, H. (2007). Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan : A Belgian analysis. Acta Clinica Belgica (Multilingual Edition), 62(6), 419-425. https://hdl.handle.net/2078.5/99575 (Original work published 2007)